广发创新药ETF联接C(012738)利润分配表
|
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
收入 |
-136,566,863.41 |
-220,872,741.58 |
-96,181,768.75 |
-97,073,768.26 |
利息合计 |
160,275.61 |
77,575.45 |
163,873.65 |
69,658.92 |
其中:存款利息收入 |
160,275.61 |
77,575.45 |
163,873.65 |
69,658.92 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益合计 |
-82,297,837.82 |
-53,390,682.88 |
-26,831,371.48 |
-10,568,926.54 |
其中:股票投资收益 |
-6,748,053.44 |
-3,629,202.17 |
-2,916,698.51 |
-144,050.67 |
基金投资收益 |
-75,943,429.85 |
-50,020,984.98 |
-23,973,909.75 |
-10,463,427.19 |
债券投资收益 |
5,724.73 |
1,342.46 |
- |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
387,920.74 |
258,161.81 |
59,236.78 |
38,551.32 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
-54,838,489.61 |
-167,699,631.19 |
-69,892,263.57 |
-86,740,428.61 |
其他收入 |
409,188.41 |
139,997.04 |
377,992.65 |
165,927.97 |
费用 |
1,626,064.78 |
829,219.32 |
1,537,212.07 |
619,956.63 |
管理人报酬 |
325,165.22 |
174,930.66 |
263,133.42 |
98,986.78 |
基金托管费 |
65,033.09 |
34,986.13 |
52,626.71 |
19,797.38 |
销售服务费 |
1,057,682.33 |
530,475.12 |
1,045,453.93 |
421,841.39 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
178,184.14 |
88,827.41 |
175,998.01 |
79,331.08 |
利润总额 |
-138,192,928.19 |
-221,701,960.90 |
-97,718,980.82 |
-97,693,724.89 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年